Poirot M - Search Results

1

Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.

de Médina P, Favre G, Poirot M. de Médina P, et al. Among authors: poirot m. Curr Med Chem Anticancer Agents. 2004 Nov;4(6):491-508. doi: 10.2174/1568011043352696. Curr Med Chem Anticancer Agents. 2004. PMID: 15579015 Review.

2

Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS).

Poirot M, De Medina P, Delarue F, Perie JJ, Klaebe A, Faye JC. Poirot M, et al. Bioorg Med Chem. 2000 Aug;8(8):2007-16. doi: 10.1016/s0968-0896(00)00119-x. Bioorg Med Chem. 2000. PMID: 11003145

3

Identification of two tamoxifen target proteins by photolabeling with 4-(2-morpholinoethoxy)benzophenone.

Mésange F, Sebbar M, Capdevielle J, Guillemot JC, Ferrara P, Bayard F, Poirot M, Faye JC. Mésange F, et al. Among authors: poirot m. Bioconjug Chem. 2002 Jul-Aug;13(4):766-72. doi: 10.1021/bc015588t. Bioconjug Chem. 2002. PMID: 12121132

4

Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.

Doisneau-Sixou SF, Cestac P, Chouini S, Carroll JS, Hamilton AD, Sebti SM, Poirot M, Balaguer P, Faye JC, Sutherland RL, Favre G. Doisneau-Sixou SF, et al. Among authors: poirot m. Endocrinology. 2003 Mar;144(3):989-98. doi: 10.1210/en.2002-220726. Endocrinology. 2003. PMID: 12586776

5

Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells.

de Medina P, Payré BL, Bernad J, Bosser I, Pipy B, Silvente-Poirot S, Favre G, Faye JC, Poirot M. de Medina P, et al. Among authors: poirot m. J Pharmacol Exp Ther. 2004 Mar;308(3):1165-73. doi: 10.1124/jpet.103.060426. Epub 2003 Nov 14. J Pharmacol Exp Ther. 2004. PMID: 14617686

6

Molecular characterization of the microsomal tamoxifen binding site.

Kedjouar B, de Médina P, Oulad-Abdelghani M, Payré B, Silvente-Poirot S, Favre G, Faye JC, Poirot M. Kedjouar B, et al. Among authors: poirot m. J Biol Chem. 2004 Aug 6;279(32):34048-61. doi: 10.1074/jbc.M405230200. Epub 2004 Jun 2. J Biol Chem. 2004. PMID: 15175332 Free article.

7

Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators.

de Medina P, Casper R, Savouret JF, Poirot M. de Medina P, et al. Among authors: poirot m. J Med Chem. 2005 Jan 13;48(1):287-91. doi: 10.1021/jm0498194. J Med Chem. 2005. PMID: 15634023

8

Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.

Dalenc F, Giamarchi C, Petit M, Poirot M, Favre G, Faye JC. Dalenc F, et al. Among authors: poirot m. Breast Cancer Res. 2005;7(6):R1159-67. doi: 10.1186/bcr1357. Epub 2005 Nov 21. Breast Cancer Res. 2005. PMID: 16457696 Free PMC article.

9

The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors.

de Medina P, Boubekeur N, Balaguer P, Favre G, Silvente-Poirot S, Poirot M. de Medina P, et al. Among authors: poirot m. J Pharmacol Exp Ther. 2006 Oct;319(1):139-49. doi: 10.1124/jpet.106.104349. Epub 2006 Jul 11. J Pharmacol Exp Ther. 2006. PMID: 16835370

10

Insights into the cholecystokinin 2 receptor binding site and processes of activation.

Paillasse MR, Deraeve C, de Medina P, Mhamdi L, Favre G, Poirot M, Silvente-Poirot S. Paillasse MR, et al. Among authors: poirot m. Mol Pharmacol. 2006 Dec;70(6):1935-45. doi: 10.1124/mol.106.029967. Epub 2006 Sep 22. Mol Pharmacol. 2006. PMID: 16998007

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters